IMP: Explanation for business results in QIII/2011

Imexpharm Pharmaceutical JSC (HOSE: IMP) has explained the fluctuation over 10% of profit after tax in QIII/2011compared with in QIII/2010 consolidated as follows:

Net revenue decreased by 18.61%, cost of goods sold decreased by 27.91% leading to gross profit decreased by 6.69% or by VND6.05 billion. Beside, selling expenses decreased by 8.4%, administrative decreased by 2.7% leading to profit before tax increased by 1.38% or by VND395 million

However, corporate income tax expenses increased by VND5.12 billion as the firm was levied a tax rate of 25% from 2011 and the Cephalosporin factory in Binh Duong did not enjoy tax exemption in the period. Therefore, profit after tax in Q3/2011 was down 17.09% from Q3/2010.

HOSE

>   TLH: Resolution of the Board of Directors (11/11/2011)

>   UDC: Record date for consulting shareholders (09/11/2011)

>   BTP: Business operational explanation (08/11/2011)

>   DQC: Resolution of the BOD (08/11/2011)

>   SBT: Resolution of the BOD (08/11/2011)

>   TIE: Business operational explanation (08/11/2011)

>   MAFPF1: NAV from 27 Oct 2011 to 03 Nov 2011 (08/11/2011)

>   THB: Business operational explanation (08/11/2011)

>   DIH: Business operational explanation (08/11/2011)

>   SJE: Business operational explanation (08/11/2011)